


PRODUCT INFORMATION



GSK2795039

Item No. 33777

CAS Registry No.: 1415925-18-6
Formal Name: N-[3-(2,3-dihydro-1-methyl-1H-indol-6-yl)-1-(1-methylethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-methyl-1H-pyrazole-3-sulfonamide
MF: C₂₃H₂₆N₆O₂S
FW: 450.6
Purity: ≥98%
UV/Vis.: λ_{max}: 234 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK2795039 is supplied as a solid. A stock solution may be made by dissolving the GSK2795039 in the solvent of choice, which should be purged with an inert gas. GSK2795039 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of GSK2795039 in these solvents is approximately 30 mg/ml.

GSK2795039 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK2795039 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GSK2795039 has a solubility of approximately 0.20 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2; IC₅₀ = 0.269 μM).¹ It is selective for NOX2 over NOX1, -3, -4, and -5 (IC₅₀s = >1,000 μM for all), as well as xanthine oxidase and PKCβ (IC₅₀s = 28.8 and 10 μM, respectively). GSK2795039 inhibits NOX2-mediated production of reactive oxygen species (ROS) and NADPH depletion in cell-free assays (IC₅₀s = 0.537 and 0.251 μM, respectively). *In vivo*, GSK2795039 (100 mg/kg) reduces serum levels of amylase, a marker for pancreatic cell necrosis, in a gp91^{phox} knockout mouse model of acute pancreatitis. GSK2795039 also inhibits brain NOX2 activity, decreases neurite shortening and apoptosis, and attenuates neurological deficits in a mouse model of weight drop-induced traumatic brain injury (TBI).²

References

1. Hirano, K., Chen, W.S., Chueng, A.L.W., et al. Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. *Antioxid. Redox Signal.* **23(5)**, (2015).
2. Wang, M. and Luo, L. An effective NADPH oxidase 2 inhibitor provides neuroprotection and improves functional outcomes in animal model of traumatic brain injury. *Neurochem. Res.* **45(5)**, 1097-1106 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM